Industry Briefs

The U.S. Patent Office, Inc.? The latest scheme to speed patent processing would give the Patent and Trademark Office quasi-corporation status. The study, prepared by a panel from the National Academy of Public Administration at the behest of the Washington, D.C.-based lobbying group Intellectual Property Owners, suggests that the office should become a semiautonomous unit within the Department of Commerce. The proposal, which has yet to be endorsed by the IPO, would give the new office the po

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The latest scheme to speed patent processing would give the Patent and Trademark Office quasi-corporation status. The study, prepared by a panel from the National Academy of Public Administration at the behest of the Washington, D.C.-based lobbying group Intellectual Property Owners, suggests that the office should become a semiautonomous unit within the Department of Commerce. The proposal, which has yet to be endorsed by the IPO, would give the new office the power to offer more competitive salaries, borrow money, and ignore government hiring freezes. ft would also exempt the Patent and Trademark Office from the Gramm-Rudman-Hollings Deficit Reduction Law, which enabled Congress to take $5 million from the bureau’s treasury in 1986. Among those hoping the restructured bureau would attract more knowledgeable and experienced examiners is the biotech industry, which now waits 30 months for review of a typical patent application. IPO executive director Herbert Wamsley, whose group represents ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies